Comparison · NCT03284424-deaths
Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course vs Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course vs Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course: deaths from any cause. Trial comparisons, record NCT03284424-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03284424-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.61 | 0.533 | 0.682 | wilson | |
| Risk in group 2 | 0.333 | 0.0615 | 0.792 | wilson | |
| Risk difference, group 1 minus group 2 | 0.277 | -0.189 | 0.558 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.83 | 0.368 | 9.11 | log | |
| Odds ratio, group 1 over group 2 | 3.13 | 0.278 | 35.2 | log | |
Number needed to harm, for one more death from any cause on Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course than on Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course | 3.61 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course | Participants received pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months). | 97 | 159 | EG000 |
| Group 2 | Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course | Eligible participants who stopped the initial course of pembrolizumab but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion. | 1 | 3 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Up to approximately 56 months
Source ClinicalTrials.gov
Trial
- Title
- Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
- NCT number
- NCT03284424
- Phases
- PHASE2
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Pembrolizumab
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2021-11-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03284424?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03284424-deaths